For multi-drug resistant (MDR) bacteria infected patients who urgently need to receive effective antibiotic therapy, A4 is a novel peptide-based antibiotic that effectively kills MDR bacteria with low propensity to elicit drug resistance. Unlike existing antibiotics or other natural antimicrobial peptides (AMPs), the A4-AMP is derived from a naturally secreted antimicrobial protein in human airways with significantly enhanced bactericidal activity against MDR pathogens. Therefore, our product is both potent and safe to use.
A4 is an antimicrobial peptide-based antibiotics that target emerging antibiotic resistance. In both in vitro and in vivo preclinical testing, A4 has shown broad-spectrum bactericidal activity against a number of both gram-positive and gram-negative bacteria. A4 has the potential to become the next generation of potent antimicrobial agents to combat common, but dangerous (especially multiple drug resistant; MDR) bacterial infections.
- First new class of antibiotics in over the last 30 years
- Novel mechanism of action is expected to still possess strong efficacy against infections
- A4-AMPs is in a fast-developing peptide-based antibiotic market that currently has limited competitors
- Respiratory tract infections
- Bacterial meningitis
- Urinary tract infections
- Skin infections
- Other MDR conditions
A provisional patent application was filed in 2016.
Stage of Development
Screening experiments in vitro have validated the excellent safety profile, the low propensity for drug resistance, and the strong antimicrobial activity of A4-AMPs against various superbugs. A selected lead compound of A4-AMPs was also successfully tested in vivo using mice, fully validating its safety and efficacy. Given the strategic need for new antimicrobials, clinical trials would likely be FDA fast-tracked when the IND is filed, and breakthrough status would be conferred upon a successful Phase 2 clinical trial.